FOOT & ANKLE
COA: Amplex appears to be an effective bone graft alternative in foot & ankle fusions
24 patients undergoing foot and ankle arthrodesis surgery were randomized to receive either an autogenous bone graft or Amplex (containing B2A, a synthetic peptide), to compare the safety and efficacy of each treatment. Radiographic assessments demonstrated that fusion success rates were high and similar between both groups. Furthermore, from baseline to 12 months pain and disability Ankle Osteoarthritis Scale (AOS) scores improved similarly for both groups and there were no adverse events related to the graft material reported by any patients.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
